Efficacy and Safety of Guselkumab vs Adalimumab for Continuous Treatment of Moderate to Severe Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared With Adalimumab for the Continuous Treatment of Patients With Moderate to Severe Psoriasis: Results From the Phase III, Double-Blinded, Placebo- and Active Comparator-Controlled VOYAGE 1 Trial
J Am Acad Dermatol 2016 Dec 29;[EPub Ahead of Print], A Blauvelt, KA Papp, CE Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, AB KimballFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.